14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NUVB vs CVAC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas CVAC carries 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin).
Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. CVAC 60.2/100 BUY), CVAC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (573.0% vs. -61.2% operating margin) and revenue trajectory (-89.0% vs. +242.6% YoY).
Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile CVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NUVB vs CVAC. Trailing 12-month operating profitability (NUVB -61.2% vs CVAC 573.0%) and valuation multiples (NUVB N/M vs CVAC 5.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CVAC Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 573.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NUVB vs CVAC Key Questions & Quantitative Answers
As of Nov 20, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas CVAC carries 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. CVAC 60.2/100 BUY), CVAC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (573.0% vs. -61.2% operating margin) and revenue trajectory (-89.0% vs. +242.6% YoY). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile CVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with CVAC at -89.0% YoY revenue growth and +24.0% YoY earnings growth on $71M TTM revenue (93.3% gross margin, 573.0% operating margin). On trailing 12-month operating scale, NUVB generates $202M in USD-normalized revenue versus $71M for CVAC. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVAC.
CVAC screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas CVAC trades at 5.2x Forward P/E, 7.0x Trailing P/E, N/M PEG, and 14.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus CVAC (40.2% ROE) capital efficiency.
In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, CVAC carries 63.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.20β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.